Sunshine Biopharma Inc. reports developments as a pharmaceutical company with commercial generic prescription drugs in Canada and proprietary drug-development programs in oncology and antivirals. News commonly covers product launches through its Nora Pharma subsidiary, including generic medicines such as Domperidone, Doxycycline and Pravastatin, as well as Health Canada commercialization approvals and expansion of therapeutic categories.
The company’s updates also address financial results, portfolio growth and research programs including K1.1 mRNA, an mRNA-lipid nanoparticle candidate targeting liver cancer, and a PLpro protease inhibitor for SARS-related coronavirus infections. Corporate and treasury actions may appear alongside operating updates when they affect Sunshine Biopharma’s capital strategy or public-company profile.
Sunshine Biopharma (NASDAQ:SBFM) closed its public offering, raising approximately $6.0 million in gross proceeds before placement agent fees and other offering expenses.
The offering comprised 10,909,082 Common Units or Pre-Funded Units, priced at $0.55 or $0.54999 each, respectively. Each unit included one common share or one Pre-Funded Warrant, plus two Series D Warrants. Each Series D Warrant initially permits purchase of one common share at $0.66. Full cash exercise of the Series D Warrants would provide approximately $14.4 million in additional gross proceeds. Sunshine Biopharma expects to use net proceeds for general corporate purposes and working capital.
Sunshine Biopharma (SBFM) priced a public offering expected to raise approximately $6.0 million in gross proceeds on a reasonable best efforts basis.
The offering comprises 10,909,083 Common Units or Pre-Funded Units, priced at $0.55 or $0.54999 each, respectively. Each unit contains one common share or one Pre-Funded Warrant, plus two Series D Warrants, each to purchase one common share at an initial exercise price of $0.66. Series D Warrants are immediately exercisable and expire five years after initial issuance. Closing is expected on or about October 9, 2026, subject to customary closing conditions. Gross proceeds are before placement agent fees and other offering expenses. The company expects to use net proceeds for general corporate purposes and working capital.
Sunshine Biopharma (SBFM) has launched generic ondansetron tablets in Canada for nausea and vomiting linked to cancer treatment.
The film-coated tablets come in 4 mg and 8 mg strengths and are the generic equivalent of Zofran. Ondansetron is prescribed for nausea and vomiting caused by chemotherapy, radiation therapy and surgery. It blocks the action of chemicals in the body that trigger those symptoms.
Sunshine Biopharma has 61 generic prescription drugs on the Canadian market. Approximately 11 additional drugs are scheduled for launch during the remainder of 2026. Its Canadian subsidiary, Nora Pharma, has an established distribution network across Canada.
Sunshine Biopharma (SBFM) has advanced its lead coronavirus PLpro inhibitor into IND-enabling studies, following preclinical work disclosed through 2026 publications.
The nominated small-molecule candidate showed nanomolar potency against the viral protease and broad-spectrum in vitro activity across SARS-CoV-2 variants of concern. It demonstrated favorable ADME characteristics, with high oral bioavailability in mice, rats and dogs, and preferential lung enrichment in mice and rats. In K18-hACE2 mice infected with human SARS-CoV-2, repeated oral dosing produced significant, dose-dependent suppression of pulmonary viral replication. Sunshine Biopharma describes this as a differentiated antiviral program with both scientific and commercial potential within its broader pipeline.
Sunshine Biopharma (NASDAQ:SBFM) announced that Health Canada has approved its Atenolol tablets (25mg, 50mg, 100mg) for sale in Canada as a generic equivalent to Tenormin® for managing cardiovascular conditions, including hypertension, angina pectoris, and post‑myocardial infarction care.
The company plans to launch Atenolol through its Canadian subsidiary Nora Pharma by the end of 2026. Sunshine Biopharma currently markets 60 generic drugs in Canada and expects to introduce about 12 additional products during the remainder of 2026, alongside ongoing proprietary programs in liver cancer and coronavirus therapies.
Sunshine Biopharma (NASDAQ:SBFM) reported that its K1.1 mRNA lipid nanoparticle (LNP) program showed in vivo tumor-suppressing activity as a single agent in at least two orthotopic hepatocellular carcinoma (HCC) mouse models, with systemic delivery, dose-dependent restoration of the target tumor suppressor, and good tolerability.
The K1.1 gene is a tumor suppressor frequently mutated in HCC, non-small cell lung cancer (NSCLC), and pancreatic cancer, leading to “cold” tumors. The company also observed antiproliferative effects in several NSCLC cell lines in vitro. The next phase will test concurrent delivery of K1.1 mRNA and a cancer vaccine targeting associated antigens in NSCLC, aiming to convert “cold” tumors into “hot” tumors and suppress growth. Sunshine Biopharma also markets 60 generic drugs in Canada and is advancing a PLpro protease inhibitor for SARS coronavirus infections.
Sunshine Biopharma (NASDAQ:SBFM) has launched its generic Amoxicillin in Canada and has begun shipping to pharmacies, offering multiple dosages and strengths. The move expands the company's portfolio of essential generic antibiotics and supports access to affordable, high-quality treatment for a wide range of bacterial infections.
According to Sunshine Biopharma, global Amoxicillin sales were about $4.9 billion in 2025 and are projected to grow at a 2.9% CAGR to roughly $6.4 billion by 2031. Canada represents approximately 2% of this global market. The company currently markets 60 generic drugs in Canada, with about 12 more launches planned for 2026.
Sunshine Biopharma (NASDAQ:SBFM) received Canadian regulatory approval for its 2mg generic Dienogest tablets, the generic equivalent of Visanne, for treatment of pelvic pain associated with endometriosis.
The company cites Dataintelo, which values the global Dienogest market at $2.8 billion in 2025, projected to reach $5.2 billion by 2034 with a 7.8% CAGR. Canada represents about 2.1% of the global pharmaceutical market and ranks sixth worldwide. Sunshine Biopharma will distribute Dienogest through its wholly owned Canadian subsidiary Nora Pharma and expects product availability for pharmacies by the end of 2026.
According to Sunshine Biopharma, the approval expands its women’s health portfolio. The company currently markets 60 generic prescription drugs in Canada, plans about 12 additional launches in 2026, and is also developing K1.1 mRNA for liver cancer and a PLpro protease inhibitor for SARS coronavirus infections.
Sunshine Biopharma (NASDAQ:SBFM) announced that Health Canada has approved its generic Ondansetron 4mg and 8mg tablets, including standard film-coated and Oral Disintegrating Tablet (ODT) forms, for the Canadian market. Ondansetron is the generic equivalent of Zofran® and is prescribed for nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery.
According to Sunshine Biopharma, the launch expands its portfolio into chemotherapy‑related nausea and vomiting, leveraging its Canadian distribution network via subsidiary Nora Pharma. The company expects Ondansetron to be ready for shipment to pharmacies by the end of 2026 and currently markets 60 generic drugs in Canada, with about 12 more scheduled for launch in 2026.
Sunshine Biopharma (NASDAQ:SBFM) announced peer‑reviewed publication in the Journal of Medicinal Chemistry of research on MR1‑114, a novel noncovalent PLpro inhibitor for SARS‑CoV‑2. MR1‑114 showed nanomolar potency in vitro across multiple variants, including the Washington strain, Delta and Omicron BA.5.
According to Sunshine Biopharma, MR1‑114 demonstrated broad‑spectrum activity, favorable ADME properties, high oral bioavailability and preferential lung enrichment in mice and rats. In the K18‑hACE2 mouse model, repeated oral dosing matched the therapeutic efficacy of Nirmatrelvir by significantly suppressing pulmonary viral replication and preventing disease‑associated weight loss.
The work, conducted with the University of Arizona, is described as an important milestone in Sunshine Biopharma’s PLpro inhibitor program for SARS Coronavirus infections. The company also highlights a commercial portfolio of 60 generic prescription drugs in Canada, with about 12 additional launches planned for 2026 and a K1.1 mRNA program for liver cancer.